Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
HOME > MHLW Expert Panel on Comprehensive Policies
MHLW Expert Panel on Comprehensive Policies
-
Think Tanks Propose New Pricing Methods for Innovative Meds, Multi-Faceted Evaluations
October 28, 2022
-
Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
October 28, 2022
-
Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
-
Nearly 700 Key Drugs Found to Be Unprofitable Due to Inflation, FX: Survey
October 24, 2022
-
Is New Expert Panel All about Drug Pricing System? Asks Chair
October 24, 2022
-
Experts Call for Debate on Scope of Health Coverage, “Exit Rule” for Unnecessary Meds
October 24, 2022
-
NHI-Market Price Gap at 20-Plus-Outlet Pharmacies 1.8 Times Larger vs. Small Hospitals
October 14, 2022
-
Experts Urge MHLW to Present Detailed Data on Generic Manufacturing Costs
October 13, 2022
-
Ways to Resolve Drug Lag/Loss, Fuel Development in Japan Up for Debate: MHLW Panel
October 13, 2022
-
Panel Members Want More Data on Allocation of NHI-Market Price Margins
October 13, 2022
-
MHLW Expert Panel Sorts Out Discussion Points for Full Debate; Focus on Innovation, Stable Supply, and Margins
October 13, 2022
-
Wholesalers Question Inflexibility in Official Pricing, Sees Limit to Addressing Rising Costs
September 30, 2022
-
Crecon President Sounds Alarm over Hollowing-Out of Domestic Manufacturing
September 30, 2022
-
Trade Group Calls for New Pricing Model for Regenerative Medicine Products
September 30, 2022
-
2% Buffer Zone Has Multiple Functions, Should Not Be Reduced: JPWA
September 30, 2022
-
Pharma Industry Faces Hurdles in Getting Medical Circle to Accept Softer Drug Price Cut Plan
September 28, 2022
-
Cost Rates of Drugs in Japan Worsen on Inflation, Weaker Yen: FPMAJ Survey
September 26, 2022
-
Japan, US, European Trade Groups Eye Introduction of “Official Margins” in Price Revision Review
September 26, 2022
-
Academic Experts Throw Candid Questions on Industry Structure, Pricing: Hearing
September 26, 2022
-
Japan Generic Industry Prods Govt to Raise Drug Prices to Ensure Stable Supply
September 26, 2022
ページ
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…